Evidence map›Paper›PMID 39247469›Full record

ArticleRadiology case reports2024

Ipilimumab and nivolumab plus radioembolization as salvage therapy for atezolizumab and bevacizumab refractory hepatocellular carcinoma resulting in complete pathologic response.

Claudia R Silver, Cynthia De la Garza-Ramos, John A Stauffer, Umair Majeed, Jianfeng Wang, Beau B Toskich

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Claudia R SilverFlorida State University College of Medicine, Tallahassee, Florida.
Cynthia De la Garza-RamosDivision of Interventional Radiology, Mayo Clinic Florida, Jacksonville, Florida.
John A StaufferDepartment of Surgery, Mayo Clinic Florida, Jacksonville, Florida.
Umair MajeedDepartment of Hematology Oncology, Mayo Clinic Florida, Jacksonville, Florida.
Jianfeng WangDepartment of Hematology Oncology, Pearlman Comprehensive Cancer Center at South Georgia Medical Center, Valdosta, Georgia.
Beau B ToskichDivision of Interventional Radiology, Mayo Clinic Florida, Jacksonville, Florida.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unresectable hepatocellular carcinoma unresponsive to first-line immunotherapy has a poor prognosis with modest response to tyrosine kinase inhibitors in the second line. In these patients, the benefit of local therapy with immunotherapy rechallenge is unknown. Radioembolization is a guideline-supported locoregional therapy for HCC that has shown the potential for synergy in combination with immunotherapy. This report describes a patient with veno-invasive HCC and extrahepatic invasion of the right kidney which progressed on atezolizumab and bevacizumab and was subsequently downstaged to resection with ipilimumab and nivolumab plus radioembolization yielding a complete pathologic response. The patient is currently more than 2 years since diagnosis without evidence of disease recurrence.

Indexed as

Combination therapiesHepatocellular carcinomaImmunotherapyPD-L1/CTLA-4 blockadeRadioembolizationY90

Identifiers

PMID39247469
PMCPMC11378113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.